清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Clinical Benefits and Risks of Anti-Amyloid Antibodies in Sporadic Alzheimer’s Disease: Systematic Review and Network Meta-Analysis with Web Application (Preprint)

预印本 荟萃分析 疾病 阿尔茨海默病 医学 万维网 计算机科学 内科学
作者
Danko Jeremic,Juan D. Navarro‐López,Lydia Jiménez‐Díaz
出处
期刊:Journal of Medical Internet Research [JMIR Publications]
标识
DOI:10.2196/68454
摘要

Despite the increasing approval of antiamyloid antibodies for Alzheimer disease (AD), their clinical relevance and risk-benefit profile remain uncertain. The heterogeneity of AD and the limited availability of long-term clinical data make it difficult to establish a clear rationale for selecting one treatment over another. The aim of this work was to assess and compare the efficacy and safety of antiamyloid antibodies through an interactive online meta-analytic approach by performing conventional pair-wise meta-analyses and frequentist and Bayesian network meta-analyses of phase II and III clinical trial results. To achieve this, we developed AlzMeta.app 2.0, a freely accessible web application that enables researchers and clinicians to evaluate the relative and absolute risks and benefits of these therapies in real time, incorporating different prior choices and assumptions of baseline risks of disease progression and adverse events. We adhered to PRISMA-NMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for reporting of systematic reviews with network meta-analysis) and GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) guidelines for reporting and rating the certainty of evidence. Clinical trial reports (until September 30, 2024) were retrieved from PubMed, Google Scholar, and clinical trial databases (including ClinicalTrials.gov). Studies with <20 sporadic AD patients and a modified Jadad score <3 were excluded. Risk of bias was assessed with the RoB-2 tool. Relative risks and benefits have been expressed as risk ratios and standardized mean differences, with confidence, credible, and prediction intervals calculated for all outcomes. For significant results, the intervention effects were ranked in frequentist and Bayesian frameworks, and their clinical relevance was determined by the absolute risk per 1000 people and number needed to treat (NNT) for a wide range of control responses. Among 7 treatments tested in 21,236 patients (26 studies with low risk of bias or with some concerns), donanemab was the best-ranked treatment on cognitive and functional measures, and it was almost 2 times more effective than aducanumab and lecanemab and significantly more beneficial than other treatments on the global (cognitive and functional) Clinical Dementia Rating Scale-Sum of Boxes (NNT=10, 95% CI 8-16). Special caution is required regarding cerebral edema and microbleeding due to the clinically relevant risks of edema for donanemab (NNT=8, 95% CI 5-16), aducanumab (NNT=10, 95% CI 6-17), and lecanemab (NNT=14, 95% CI 7-31), which may outweigh the benefits. Our results showed that donanemab is more effective and has a safety profile similar to aducanumab and lecanemab, highlighting the need for treatment options with improved safety. Potential bias may have been introduced in the included trials due to unblinding caused by frequent cerebral edema and microbleeds, as well as the impact of the COVID-19 pandemic.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_Lw7OvL完成签到 ,获得积分10
1分钟前
MADAO完成签到 ,获得积分10
1分钟前
潘啊潘完成签到 ,获得积分10
1分钟前
sysi完成签到 ,获得积分10
1分钟前
方方完成签到 ,获得积分10
1分钟前
小芳芳完成签到 ,获得积分10
1分钟前
小晨完成签到 ,获得积分10
1分钟前
jyy发布了新的文献求助200
2分钟前
海上众川归完成签到 ,获得积分10
2分钟前
心静自然好完成签到 ,获得积分10
2分钟前
wendydqw完成签到 ,获得积分10
3分钟前
发个15分的完成签到 ,获得积分10
3分钟前
Johnson完成签到 ,获得积分10
4分钟前
小井盖完成签到 ,获得积分10
4分钟前
呐殇完成签到,获得积分10
4分钟前
呐殇发布了新的文献求助10
4分钟前
无悔完成签到 ,获得积分10
4分钟前
柚C美式完成签到 ,获得积分10
4分钟前
瘦瘦的迎南完成签到 ,获得积分10
4分钟前
gao完成签到 ,获得积分10
6分钟前
科目三应助微风低回采纳,获得10
6分钟前
一个完成签到 ,获得积分10
6分钟前
wf关闭了wf文献求助
6分钟前
6分钟前
6分钟前
微风低回发布了新的文献求助10
6分钟前
微风低回完成签到,获得积分10
6分钟前
chiyudoubao完成签到,获得积分10
6分钟前
高等会完成签到,获得积分0
6分钟前
creep2020完成签到,获得积分10
6分钟前
TOUHOUU完成签到 ,获得积分10
6分钟前
illusion完成签到,获得积分10
6分钟前
7分钟前
anitachiu1104发布了新的文献求助10
7分钟前
淞淞于我完成签到 ,获得积分10
7分钟前
木木杨完成签到,获得积分10
7分钟前
8分钟前
东溟渔夫发布了新的文献求助10
8分钟前
鲁滨逊完成签到 ,获得积分10
8分钟前
房天川完成签到 ,获得积分0
8分钟前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Les Mantodea de Guyane Insecta, Polyneoptera 2500
Computational Atomic Physics for Kilonova Ejecta and Astrophysical Plasmas 500
Technologies supporting mass customization of apparel: A pilot project 450
Brain and Heart The Triumphs and Struggles of a Pediatric Neurosurgeon 400
Cybersecurity Blueprint – Transitioning to Tech 400
Mixing the elements of mass customisation 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3782710
求助须知:如何正确求助?哪些是违规求助? 3328095
关于积分的说明 10234416
捐赠科研通 3043042
什么是DOI,文献DOI怎么找? 1670442
邀请新用户注册赠送积分活动 799698
科研通“疑难数据库(出版商)”最低求助积分说明 758994